10-Q: Lyell Immunopharma Narrows Q3 Loss, Advances Key Cell Therapies

Lyell Immunopharma reported a reduced net loss in Q3 2025, driven by lower operating expenses, while advancing its lead CAR T-cell candidates ronde-cel and LYL273 into pivotal trials and further development.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $133.7 million from $151.1 million in the prior year, a $17.3 million improvement.
• Research and development expenses decreased by $16.5 million to $106.5 million for the nine months ended September 30, 2025, primarily due to reduced research activities, collaborations, outside services, and lower personnel-related expenses.
• General and administrative expenses decreased by $3.0 million to $34.5 million for the nine months ended September 30, 2025, mainly due to lower legal expenses and stock-based compensation.
• Cash, cash equivalents, and marketable securities totaled $319.6 million as of September 30, 2025, excluding restricted cash.
• The company believes its existing cash, cash equivalents, and marketable securities are sufficient to fund operations at least through 2027.
• Initiated the PiNACLE H2H Phase 3 head-to-head CAR T-cell therapy randomized controlled trial for ronde-cel in patients with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line (2L) setting, with first patient enrollment expected by early 2026.
• The pivotal PiNACLE single-arm trial for ronde-cel in 3L+ LBCL is ongoing and enrolling patients.
• Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate for refractory metastatic colorectal cancer (mCRC), with promising early Phase 1 clinical data showing a 67% overall response rate at the highest dose level.
• LYL273 received Fast Track designation from the FDA for mCRC.
• Ronde-cel received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for 3L+ LBCL, and RMAT designation for 2L LBCL.
• Successfully transitioned manufacturing of ronde-cel to the LyFE Manufacturing Center in Bothell, Washington, and plans to transition LYL273 manufacturing there as well.
• The company's LyFE Manufacturing Center is expected to manufacture over 1,200 patient CAR T-cell products per year at full capacity.
• Issued 625,000 shares of common stock valued at $5.9 million in July 2025 upon achieving a clinical milestone related to the ImmPACT Bio acquisition.
• Completed a $50.0 million equity financing in July 2025 through a Securities Purchase Agreement (SPA), with rights for an additional $50.0 million upon milestone achievement or investor call.
• Recognized a $4.0 million loss from the change in fair value of the SPA put/call asset for the nine months ended September 30, 2025, due to an increase in the company's stock price.
• Recognized a $1.4 million impairment of long-lived assets related to the planned closure of the West Hills, Los Angeles manufacturing facility.

Sentiment

Score: 7

Explanation: The company demonstrated improved financial efficiency with reduced net losses and R&D expenses, while making significant clinical progress with its lead candidates, ronde-cel and LYL273, including initiating pivotal trials and securing key regulatory designations. The cash runway into 2027 provides stability. However, the company remains pre-revenue, faces substantial future capital needs, and incurred an impairment charge, balancing the positive clinical and cost control news.

Positives

• Net loss decreased by $17.3 million for the nine months ended September 30, 2025, compared to the prior year.
• Research and development expenses decreased by $16.5 million, reflecting efficient resource allocation and cost management.
• General and administrative expenses decreased by $3.0 million, indicating improved operational efficiency.
• Strong cash position with $319.6 million in cash, cash equivalents, and marketable securities, providing runway into 2027.
• Initiation of the pivotal Phase 3 PiNACLE H2H trial for ronde-cel in 2L LBCL, targeting a significant market opportunity.
• Ongoing pivotal PiNACLE single-arm trial for ronde-cel in 3L+ LBCL continues to enroll patients.
• Positive initial Phase 1 clinical data for LYL273 in refractory mCRC, including a 67% overall response rate at the highest dose level.
• Acquisition of exclusive global rights to LYL273 expands the pipeline into solid tumors with a promising candidate.
• Ronde-cel received RMAT and Fast Track designations, and LYL273 received Fast Track designation, which may expedite regulatory review.
• Successful transition of ronde-cel manufacturing to the LyFE Manufacturing Center, enhancing control and efficiency.
• Achievement of a clinical milestone for ImmPACT Bio acquisition, leading to the issuance of 625,000 common shares.

Negatives

• Continued substantial net losses, with an accumulated deficit of $1.5 billion as of September 30, 2025.
• Revenue remains de minimis at $30,000 for the nine months ended September 30, 2025.
• Interest income, net, decreased by $8.7 million for the nine months ended September 30, 2025, due to lower interest rates and reduced cash balances.
• Incurred a $4.0 million loss on the SPA put/call asset due to stock price increase, reflecting a financial instrument valuation rather than operational loss.
• Impairment of long-lived assets of $1.4 million related to the West Hills facility closure.
• The company will require substantial additional capital beyond 2027 to fund operations and commercialization efforts.
• The CFO recently resigned, and a replacement has not yet been appointed, which could impact financial leadership.
• Workforce reductions in Q4 2023, Q4 2024, and Q1 2025 may lead to unintended consequences like difficulty retaining employees and loss of institutional knowledge.

Risks

• Incurred substantial losses since inception and anticipate continued substantial and increasing net losses for the foreseeable future.
• Limited operating history in a rapidly evolving field makes it difficult to evaluate business success and future viability.
• No products approved for sale and no revenue from product sales; may never generate revenue or achieve profitability.
• Requires substantial additional capital to achieve goals; failure to obtain necessary capital could delay, limit, reduce, or terminate product development or commercialization efforts.
• Milestone, royalty, and success payment obligations may result in dilution to stockholders or reduce cash resources, causing financial fluctuations.
• Product candidates and technology platforms are based on novel, unproven technologies, exposing the company to unforeseen risks and making development time/cost and regulatory approval difficult to predict.
• No marketing, sales, or distribution infrastructure; establishing or outsourcing this function carries substantial risks.
• Delays in qualifying or receiving regulatory approvals for manufacturing facilities, or expanding capacity, could delay development plans and limit product revenues.
• Manufacturing cellular therapies is complex and subject to risks (supply chain, contamination, equipment failure, personnel error) that could increase costs, delay programs, or limit supply.
• Reliance on third parties to manufacture product candidates could subject the company to risks and delay or prevent development/commercialization.
• Reliance on third parties for clinical trials and nonclinical studies; failure to perform satisfactorily could delay or prevent regulatory approval or commercialization.
• Past and future collaborations or strategic alliances may not realize anticipated benefits.
• Dependence on patient enrollment and retention in clinical trials; delays or difficulties could materially adversely affect R&D and business.
• Faces substantial competition in rapidly changing industries, potentially leading to others commercializing products more successfully.
• Cellular therapy product candidates represent new therapeutic approaches, potentially leading to heightened regulatory scrutiny, delays, or issues with payor coverage.
• Results of early research/clinical trials are not necessarily predictive of future results; later trials may fail to produce positive results or demonstrate satisfactory safety and efficacy.
• Interim, topline, or preliminary data from clinical trials may change as more patient data become available or manufacturing processes change, and are subject to audit/verification.
• Acquisition of ImmPACT and LYL273 may not realize anticipated benefits, including cost savings and operating efficiencies.
• International trade policies (tariffs, sanctions, trade barriers) may adversely affect business, financial condition, results of operations, and prospects.
• Unstable market and economic conditions may have serious adverse consequences on business, financial condition, and stock price.
• Inability to obtain and maintain sufficient intellectual property protection, or insufficient breadth of protection, could adversely affect commercialization and competitiveness.
• In-licensed intellectual property from partners and third parties; breach of license agreements could lead to loss of development/commercialization ability.
• May be unable to comply with Nasdaq Global Select Market continued listing requirements.
• Sales of substantial number of shares by existing stockholders could cause stock price to decline.
• Raising additional capital may cause dilution, restrict operations, or require relinquishing rights to technologies/products.
• Future acquisitions, strategic investments, partnerships, or alliances could be difficult to identify/integrate, divert management, disrupt business, dilute stockholder value, and adversely affect operating results/financial condition.
• Requirements of being a public company require substantial management time and strain resources.
• Delaware law and organizational documents might discourage, delay, or prevent a change in control or management changes.
• Exclusive forum provision in certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Failure to maintain proper and effective internal controls over financial reporting or identify additional material weaknesses could harm business and stock value.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• If securities or industry analysts do not publish research or publish negative/neutral evaluations, stock price could decline.
• Changes in tax laws or regulations may have a material adverse effect on business, cash flow, financial condition, results of operations, effective tax rate, or compliance costs.
• Indemnity provisions in various agreements potentially expose the company to substantial liability.

Future Outlook

The company expects to incur additional losses as it expands R&D, conducts clinical trials, seeks regulatory approvals, and builds manufacturing capabilities. It anticipates needing to raise additional capital beyond 2027 to fund operations and potential commercialization. The company is focused on advancing ronde-cel through pivotal trials with a Biologics License Application submission expected in 2027 for 3L+ LBCL, and further developing LYL273 with the next data update expected in H1 2026. An IND submission for a fully-armed CAR T-cell product candidate for solid tumors is expected in 2026.

Management Comments

• Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors.
• We are pioneering novel approaches designed to generate T-cell therapies that drive long-lasting clinical responses.
• We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2025 will be adequate to fund our operations at least through the next 12 months from the date these unaudited condensed consolidated financial statements are issued (into 2027).
• We view our manufacturing team and capabilities as a significant competitive advantage.
• At full staffing and capacity, we expect to be able to manufacture greater than 1,200 patient CAR T-cell products/year and support our clinical development needs for ronde-cel, LYL273 and other pipeline programs, as well as early commercial launch of ronde-cel and LYL273, if approved.

Industry Context

Lyell Immunopharma operates in the highly competitive and rapidly evolving cell therapy and biopharmaceutical industries, focusing on next-generation CAR T-cell product candidates for cancer. The company's dual-targeting approach for ronde-cel and its entry into solid tumors with LYL273 position it against established CD19 CAR T-cell therapies and emerging solid tumor cell therapies. The industry faces challenges in achieving durable responses in solid tumors and overcoming antigen escape in hematologic malignancies, which Lyell's technologies aim to address. Macroeconomic conditions, including inflation and geopolitical conflicts, continue to pose risks to the global economy and the biotechnology sector.

Comparison to Industry Standards

• Ronde-cel's dual-targeting CD19/CD20 CAR T-cell therapy is designed to improve upon first-generation CD19 CAR T-cell products like axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) by increasing complete response rates and prolonging duration of response, particularly by addressing CD19 antigen escape and lower/heterogeneous CD19 antigen density.
• The ZUMA-7 pivotal trial of axicabtagene ciloleucel demonstrated improved overall survival in patients with a higher median percentage of T cells with a naive/stem memory phenotype, which aligns with ronde-cel's manufacturing process designed to enrich for CD62L-positive naive and central memory T cells.
• LYL273's reported 67% overall response rate at the highest dose level in refractory mCRC compares favorably to approved therapies where only 6% of patients in the 3L+ setting achieve partial or complete responses, and median overall survival is generally less than 12 months.
• The manageable safety profile of ronde-cel, with low rates of Grade >3 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), is a key differentiator compared to the known side effects of other CAR T-cell therapies, potentially enabling outpatient administration.
• The company's LyFE Manufacturing Center, with a projected capacity of over 1,200 patient CAR T-cell products/year, aims to provide a competitive advantage in controlling supply chain, optimizing cost and quality, and rapidly incorporating innovations, contrasting with reliance on external contract manufacturing organizations (CMOs) common in the industry.

Management Changes

Legal Proceedings

• The company is currently not party to any legal proceedings material to its operations or of which any of its property is the subject, nor is it aware of any such proceedings that are contemplated by a government authority or otherwise.

Related Party Transactions

• In September 2021, the company entered into a sublease with Sonoma Biotherapeutics, Inc. (Sonoma), a related party with common stockholders and board seats. Dr. Klausner, the Chair of Lyell's board, also serves as Board Chair of Sonoma.
• As of September 30, 2025, and December 31, 2024, there were accrued liabilities and other current liabilities of $0.5 million and other non-current liabilities of $2.2 million and $2.5 million, respectively, in connection with the Sonoma Sublease.
• Sonoma other operating income, net, was $688,000 for the three months ended September 30, 2025, and $2.077 million for the nine months ended September 30, 2025.
• Sonoma sublease income was $466,000 for the three months ended September 30, 2025, and $1.396 million for the nine months ended September 30, 2025.
• ARCH Venture Fund XIII, L.P. participated as a Purchaser in the July 2025 Securities Purchase Agreement (SPA), acquiring approximately 0.9 million shares of common stock for $12.5 million. ARCH Venture Fund XIII, L.P. beneficially owned greater than 10% of the company's outstanding common stock as of July 2025.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future capital raises (ATM, SPA), but also potential for value creation from clinical advancements and regulatory approvals. Stock price volatility is a noted risk.
• **Employees:** Workforce reductions have occurred, potentially impacting morale and retention. The company is highly dependent on attracting and retaining skilled personnel. Stock-based compensation is a significant component of compensation.
• **Customers (future patients):** Advancement of ronde-cel and LYL273 offers potential new treatment options for LBCL and mCRC, addressing unmet medical needs.
• **Suppliers/Partners:** Continued reliance on third parties for research, clinical trials, and raw materials. Supply chain disruptions and compliance issues with third-party manufacturers are risks.
• **Creditors:** The company has no debt outstanding as of September 30, 2025, reducing immediate creditor risk, but future debt financing could increase fixed payment obligations.

Next Steps

• Enroll the first patient in the PiNACLE H2H Phase 3 trial by early 2026.
• Present updated data from the PiNACLE trial at the American Society of Hematology (ASH) 67th Annual Meeting and Exposition in December 2025.
• Expect the next data update for LYL273 in the first half of 2026.
• Submit a Biologics License Application (BLA) to the FDA in 2027 for ronde-cel in 3L+ LBCL.
• Submit the first Investigational New Drug (IND) application for a fully-armed CAR T-cell product candidate for solid tumors in 2026.
• Continue to evaluate third-party manufacturing options to build scale and reduce cost for CAR T-cell manufacturing.
• Transition manufacturing of LYL273 to the LyFE Manufacturing Center.

Key Dates

Recommendation

Lyell Immunopharma is a clinical-stage biotech with a promising pipeline, particularly with ronde-cel entering pivotal trials and the acquisition of LYL273 showing encouraging early data. The company has demonstrated improved financial management by reducing net losses and R&D expenses, and its cash runway into 2027 provides a reasonable period of liquidity. However, it remains pre-revenue, faces significant future capital requirements for commercialization, and operates in a highly competitive and risky industry. While the clinical progress and regulatory designations are positive, the inherent uncertainties of drug development, potential for dilution from future capital raises, and the recent CFO resignation warrant a 'hold' recommendation. Investors should monitor clinical trial readouts, regulatory progress, and future financing activities closely before making further investment decisions.

Keywords

Cell Therapy, CAR T-cell, Immunopharma, Oncology, Large B-cell Lymphoma, Colorectal Cancer, Ronde-cel, LYL314, LYL273, Clinical Trials, Biotechnology, SEC Filing, 10-Q, Financial Results, Research and Development, Biologics, RMAT, Fast Track, Manufacturing, ImmPACT Bio, Innovative Cellular Therapeutics